 "MannKind regains marketing rights for inhaled insulin Afrezza from Sanofi")
MannKind Corporation has assumed responsibility for the worldwide development and commercialisation of Afrezza (insulin human) inhalation powder from Sanofi, effective April 5, 2016, in a transition that ensures patients will not experience any interruption in their treatment. Under terms of the transfer agreement, Sanofi will continue to distribute Afrezza from its existing inventory until MannKind begins to distribute Afrezza during the third quarter.
“Today's return of control of Afrezza is a landmark day for MannKind. We are thrilled to begin the process of making Afrezza the successful mealtime treatment for people with diabetes that we always believed it would be. In the coming weeks, we will roll out more information about our commercial team for Afrezza, the resources that we are designing for patients and physicians, and our plans for the future,” said Matthew Pfeffer, Chief Executive Officer of MannKind.
Afrezza, approved in 2014 by the US Food and Drug Administration (FDA), is a rapid-acting inhaled insulin therapy indicated to improve glycemic control in adult patients with diabetes. Taken at the start of a meal using a specially designed inhaler, Afrezza dissolves rapidly upon inhalation to the deep lung and delivers insulin quickly to the bloodstream. Peak insulin levels are achieved within 12 to 15 minutes of use and help to control post-meal blood sugar spikes that affect HbA1C levels.
Afrezza is not a substitute for long-acting insulin but must be used in combination with long-acting insulin in patients with type 1 diabetes.
“Today's return of control of Afrezza is a landmark day for MannKind. We are thrilled to begin the process of making Afrezza the successful mealtime treatment for people with diabetes that we always believed it would be. In the coming weeks, we will roll out more information about our commercial team for Afrezza, the resources that we are designing for patients and physicians, and our plans for the future,” said Matthew Pfeffer, Chief Executive Officer of MannKind.
Afrezza, approved in 2014 by the US Food and Drug Administration (FDA), is a rapid-acting inhaled insulin therapy indicated to improve glycemic control in adult patients with diabetes. Taken at the start of a meal using a specially designed inhaler, Afrezza dissolves rapidly upon inhalation to the deep lung and delivers insulin quickly to the bloodstream. Peak insulin levels are achieved within 12 to 15 minutes of use and help to control post-meal blood sugar spikes that affect HbA1C levels.
Afrezza is not a substitute for long-acting insulin but must be used in combination with long-acting insulin in patients with type 1 diabetes.